Unmasking PD-1 Resistance by Next-Generation Sequencing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Investigating POU3F4 in cancer: Expression patterns, prognostic implications, and functional roles in tumor immunity.Heliyon · 2025
   Article
2. Comprehensiveness cuproptosis related genes study for prognosis and medication sensitiveness across cancers, and validation in prostate cancer.Scientific reports · 2024
   Article
3. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges.Frontiers in immunology · 2024
   Review
4. Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance.Scientific reports · 2023
   Article
5. A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance.Scientific reports · 2023
   Article
6. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.Cellular & molecular immunology · 2022
   Article
7. Exploring immunotherapy in colorectal cancer.Journal of hematology & oncology · 2022
   Review
8. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.Frontiers in pharmacology · 2022
   Article
9. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.Immunology · 2019
   Review
10. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.Frontiers of medicine · 2018
    Article
11. Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.Frontiers in oncology · 2018
    Review
12. Checkpoint Inhibitors for Advanced Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2016
    Article

Corrections and comments

• Comment on
  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.2016

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as